Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung cancers are non-small cell lung cancers, in which tumor cells are larger and ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

New clinical evidence indicates that a widely used supplement may alter gut microbes involved in vitamin D biology and ...

A new study reveals how a single cancer protein may simultaneously drive tumor survival and metabolic control, uncovering a hidden link between two core features of cancer. Scientists have uncovered a ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit Looks Back at Pancreatic Cancer in 2025: A Year of Progress, ...

One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...

Researchers at Karolinska Institutet have identified small molecules capable of influencing a hard-to-target receptor family linked to cancer development. The findings have been published in Nature ...